Detalles de la búsqueda
1.
Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments.
Mol Cancer;
23(1): 15, 2024 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38225603
2.
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
BMC Med;
22(1): 42, 2024 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38281914
3.
Transcriptome and open chromatin analysis reveals the process of myocardial cell development and key pathogenic target proteins in Long QT syndrome type 7.
J Transl Med;
22(1): 307, 2024 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38528561
4.
Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Inflamm Res;
73(2): 263-276, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38200372
5.
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Cancer Immunol Immunother;
72(9): 2949-2960, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37247023
6.
Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis.
Brief Bioinform;
22(4)2021 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33051665
7.
Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma.
BMC Cancer;
23(1): 451, 2023 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37202783
8.
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer.
Cancer Immunol Immunother;
71(8): 1889-1896, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022908
9.
Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
BMC Med;
19(1): 154, 2021 07 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34284787
10.
Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression.
J Cell Physiol;
234(10): 18837-18848, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30916406
11.
Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma.
Cancer Cell Int;
19: 90, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31007608
12.
A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma.
J Cell Mol Med;
22(12): 5928-5938, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30247807
13.
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression.
BMC Cancer;
18(1): 766, 2018 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30055582
14.
Association of chronic liver disease with the prognosis of COVID-19 patients.
J Hepatol;
76(1): 228-229, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34293343
15.
Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease.
J Hepatol;
74(6): 1493-1494, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33476746
16.
Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.
Int Immunopharmacol;
126: 111281, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38061115
17.
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Int J Surg;
2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704621
18.
Multidisciplinary management of hepatobiliary tumors in the era of precision medicine.
Hepatobiliary Pancreat Dis Int;
17(5): 381-382, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30082196
19.
Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers.
Transl Res;
256: 14-29, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36586534
20.
Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
Front Immunol;
14: 1109292, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36742297